Techno Drugs Ltd. announcements
59 Dhaka Stock Exchange announcements for Techno Drugs Ltd. (TECHNODRUG) since 2024: results, dividends, board meetings, AGMs, record dates and other price-sensitive information. Showing 2024 (16).
- Resumption after Record Date
Trading of the shares of the company will resume on 19.11.2024.
- Q1 Financials
(Q1 Un-audited): EPS was Tk. 0.63 for July-September, 2024 as against Tk. 1.09 for July-September, 2023; NOCFPS was Tk. 0.23 for July-September, 2024 as against Tk. 1.51 for July-September, 2023. NAV per share (with revaluation) was Tk. 29.88 as on September 30, 2024 and Tk. 33.50 as on June 30, 2024. NAV per share (without revaluation) was Tk. 26.19 as on September 30, 2024 and Tk. 28.33 as on June 30, 2024. Reasons for significant deviation in EPS, NOCFPS and NAVPS: (cont.) (Continuation news of TECHNODRUG): This is because sales have come down to Tk. 102 crore from Tk. 145 crore in the first quarter than the first quarter of previous year. The reason behind of low sales value is Government did not procure as much as they did in the last year. In addition, recently issued shares for IPO, resulting in increasing 3,78,40,788 shares. These increased shares also played a part. Altogether resulted in reducing EPS, Cash Flow from Operation and NAV in the first quarter. (end)
- Suspension for Record date
Trading of the shares of the company will remain suspended on record date i.e., 18.11.2024.
- Spot News
Trading of the shares of the company will be allowed only in the Spot Market and Block transaction will also be settled as per spot settlement cycle with cum benefit from 14.11.2024 to 17.11.2024 and trading of the shares of the company will remain suspended on record date i.e., 18.11.2024.
- Board Meeting schedule under LR 16(1)
As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on November 14, 2024 at 3:30 PM to consider, among others, un-audited financial statements of the Company for the First Quarter (Q1) period ended September 30, 2024.
- The Board of Directors has recommended 12\% Cash Dividend only for general shareholders other than Board of Directors fo
The Board of Directors has recommended 12\% Cash Dividend only for general shareholders other than Board of Directors for the year ended June 30, 2024. Directors/ sponsor are holding 82,776,200 shares and General Public are holding 49,221,988 shares. Cash dividend payable to General Public is Tk. 59,066,386.00. Date of AGM: 26.12.2024, Time: 10:00 AM, Venue: The AGM will be conducted through Hybrid System in combination of Physical Presence at Institution of Diploma Engineers, (cont.)
- Dividend Declaration
(Continuation news of TECHNODRUG): 160/A, Kakrail VIP Road, Dhaka 1000 and Digital Platform through the link https://technodrug.digitalagmbd.net. Record date: 18.11.2024. The Company has also reported EPS of Tk. 2.94, NAV per share with revaluation of Tk. 33.50, NAV per share without revaluation of Tk. 28.33 and NOCFPS of Tk. 4.48 for the year ended June 30, 2024 as against Tk. 2.08, Tk. 27.74, Tk. 22.57 and Tk. 2.23 respectively for the year ended June 30, 2023. (end)
The first part of this announcement is missing from the archive. - Price Limit Open
There will be no price limit on the trading of the shares of the Company today (28.10.2024) following its corporate declaration.
- Credit Rating Result
Emerging Credit Rating Limited (ECRL) has affirmed surveillance rating of the Company as "A-" in the long term and "ST-3" in the short term along with a Stable outlook based on audited financial statements of FY 2020-2023, Nine months unaudited financial statements up to march 31, 2024 and other quantitative information available up to the date of rating.
- Board Meeting schedule under LR 19(1)
As per Regulation 19(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on October 27, 2024 at 3:00 PM to consider, among others, audited financial statements of the Company for the year ended June 30, 2024.
- Techno Drugs Limited: (Q3): As per un-audited Q3 financial statements, profit after tax was BDT 39.13 million and basic
Techno Drugs Limited: (Q3): As per un-audited Q3 financial statements, profit after tax was BDT 39.13 million and basic EPS BDT 0.42 for the 03 (three) months (January-March, 2024) period ended on 31 March 2024 as against profit after tax of BDT 29.59 million and basic EPS of BDT 0.31 for the same period of the previous year. However, Post-IPO basic EPS for the 03 (three) months (January-March 2024) period ended on 31 March 2024 would be BDT 0.30. (cont.1)
- (Continuation news of TECHNODRUG): Moreover, profit after tax was BDT 242.93 million and basic EPS of BDT 2.58 for the 9
(Continuation news of TECHNODRUG): Moreover, profit after tax was BDT 242.93 million and basic EPS of BDT 2.58 for the 9 (nine) months (July\'23-March\'24) period ended on 31 March 2024 as against profit after tax of BDT 178.53 million and basic EPS of BDT 1.90 for the same period of the previous year. However, Post-IPO EPS would be BDT 1.84 for 09 (nine) months (July\'23- March\'24) period ended on 31 March 2024. (cont.2)
The first part of this announcement is missing from the archive. - (Continuation news of TECHNODRUG): Pre-IPO Net Asset Value (NAV) per share with revaluation reserve (considering Pre-IPO
(Continuation news of TECHNODRUG): Pre-IPO Net Asset Value (NAV) per share with revaluation reserve (considering Pre-IPO paid up shares) would be BDT 30.32 as on 31 March 2024 and the same would be BDT 29.21 (considering Post-IPO paid up shares). Pre-IPO Net Asset Value (NAV) per share without revaluation reserve (considering Pre-IPO paid up shares) would be BDT 25.15 as on 31 March 2024 and the same would be BDT 25.51 (considering Post-IPO paid up shares). (cont.3)
The first part of this announcement is missing from the archive. - Trading of Shares of Techno Drugs Limited
Trading of shares of Techno Drugs Limited will start from today i.e., July 14, 2024 under the main market of DSE. Trading Code and Company code for Techno Drugs Limited at DSE will be "TECHNODRUG" and "18499" respectively under "Pharmaceuticals & Chemicals" Sector.
- Prohibition on providing loan facilities to purchase securities
DSE NEWS: The Stock Brokers, Merchant Bankers and Portfolio Managers are requested to abstain from providing loan facilities to purchase securities of Techno Drugs Ltd. in between 1st to 30th trading day starting from today i.e., July 14, 2024 as per BSEC Directive No. BSEC/CMRRCD/2009-193/32 dated December 26, 2021.
- Q3 Financials of Techno Drugs Limited
(Continuation news of TECHNODRUG): Pre-IPO weighted average paid-up number of shares for 03 (three) months (January-March, 2024) and 09 (nine) months (July'23- March'24) period ended on 31 March 2024 was 94,157,400 which was same for the same period of the previous year. However, Post-IPO paid-up number of shares would be 131,998,188. (end)
The first part of this announcement is missing from the archive.
Source: Dhaka Stock Exchange announcements. Some posts before 2014 have no title, and 2014–2020 coverage is incomplete.